drugset
drugset / Trial / NCT03883984

Cysteamine for Asthma

NCT03883984 ↗

Phase 1 Completed 60 enrolled Children's Hospital Medical Center, Cincinnati
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.

Timeline

Start
2019-06-18
Primary completion
2021-02-10
Completion
2021-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cysteamine Unknown 125 mg —

Indications

asthma